• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Real-World Effectiveness and Safety of Risankizumab in Adult Patients with Plaque Psoriasis: A 16-Week International Multicenter Retrospective Cohort Study.

作者信息

Bagit Ahmed, Maliyar Khalad, Mansour Mark, Georgakopoulos Jorge R, Rankin Brian D, Lytvyn Yuliya, Zaaroura Hiba, Park Ye-Jean, Wang Ou Jia Emilie, Mufti Asfandyar, Torres Tiago, Le Ana M, Vender Ronald, Prajapati Vimal H, Yeung Jensen

机构信息

Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.

Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada.

出版信息

J Cutan Med Surg. 2024 Nov-Dec;28(6):604-605. doi: 10.1177/12034754241274300. Epub 2024 Sep 3.

DOI:10.1177/12034754241274300
PMID:39225249
Abstract
摘要

相似文献

1
Real-World Effectiveness and Safety of Risankizumab in Adult Patients with Plaque Psoriasis: A 16-Week International Multicenter Retrospective Cohort Study.司库奇尤单抗在成人斑块状银屑病患者中的真实世界有效性和安全性：一项为期16周的国际多中心回顾性队列研究。
J Cutan Med Surg. 2024 Nov-Dec;28(6):604-605. doi: 10.1177/12034754241274300. Epub 2024 Sep 3.
2
Real-world effectiveness and safety of risankizumab in adult patients with plaque psoriasis: A 1-year international multicenter retrospective cohort study.司库奇尤单抗在成年斑块状银屑病患者中的真实世界有效性和安全性：一项为期1年的国际多中心回顾性队列研究。
J Am Acad Dermatol. 2024 Sep;91(3):513-515. doi: 10.1016/j.jaad.2024.03.048. Epub 2024 Apr 25.
3
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS).司库奇尤单抗在真实世界环境中的有效性、耐受性和药物留存率：一项为期三年的回顾性多中心研究-IL PSO（意大利银屑病概况）
J Clin Med. 2024 Jan 16;13(2):495. doi: 10.3390/jcm13020495.
4
Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class.近期古塞库单抗治疗失败的斑块状银屑病患者中瑞莎珠单抗的真实世界有效性和安全性：一项白细胞介素-23抑制剂类药物转换的多中心回顾性研究
JAAD Int. 2023 May 26;12:136-138. doi: 10.1016/j.jdin.2023.05.006. eCollection 2023 Sep.
5
Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study.利纳西珠单抗治疗中重度斑块状银屑病的真实世界疗效和安全性：一项 40 周的多中心回顾性研究。
Acta Derm Venereol. 2021 Nov 30;101(11):adv00605. doi: 10.2340/actadv.v101.283.
6
Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study.司库奇尤单抗治疗中度至重度银屑病的长期疗效和安全性：一项为期2年的真实世界回顾性研究
J Clin Med. 2023 Apr 30;12(9):3233. doi: 10.3390/jcm12093233.
7
Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study.司库奇尤单抗治疗131例中重度斑块状银屑病患者的真实疗效及安全性：一项52周回顾性研究
Dermatol Ther (Heidelb). 2022 Oct;12(10):2309-2324. doi: 10.1007/s13555-022-00795-x. Epub 2022 Sep 5.
8
Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study.临床实践中瑞莎珠单抗治疗中重度斑块状银屑病的疗效和安全性：一项为期16周的加拿大回顾性多中心队列研究。
JAAD Int. 2021 Nov 9;6:3-5. doi: 10.1016/j.jdin.2021.09.007. eCollection 2022 Mar.
9
Risankizumab treatment in psoriasis patients who failed anti-IL17: A 52-week real-life study.利纳西珠单抗治疗抗 IL17 治疗失败的银屑病患者：一项 52 周的真实世界研究。
Dermatol Ther. 2022 Jul;35(7):e15524. doi: 10.1111/dth.15524. Epub 2022 Apr 26.
10
Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.司库奇尤单抗与瑞莎珠单抗治疗中度至重度斑块状银屑病患者的疗效与安全性比较（IMMerge）：一项III期随机开放标签、疗效评估者设盲临床试验的结果
Br J Dermatol. 2021 Jan;184(1):50-59. doi: 10.1111/bjd.19341. Epub 2020 Sep 6.